Nath Bio-Genes (India) Limited

Agricultural Commodities/Milling/ NSE

Compiled

Auto-generated from filings and public channels — no analyst dossier.

If management delivers what it guided

arithmetic on filed guidance and past valuations · not a price target

NATHBIOGEN

FY26 → FY27 · 1 year of guidance · ~0.7 years from today₹159 today

BEAR

₹156

-2%

10.1% a year · 6.5x exit

BASE

₹196

+23%

17.5% a year · 7.6x exit

BULL

₹224

+41%

23.8% a year · 8.3x exit

Where the market has priced it

6x7x today9x

multiple band rests on only 4 filed years
this company's own median multiple sits 64% below its filed-industry peers; the scenario uses its own

How these numbers are produced

Earnings base	FY26 fiscal year EPS ₹21.91 (screener)
Guided growth	17.5% a year, said on the call of 11-May-2026 · transcript
Read across as	operating: revenue growth, margin held flat — medium confidence
Delivery calibration	0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings
Exit multiple	6.45x / 7.6x / 8.27x, this company’s own p20 / median / p80 across 4 filed years
Filed-industry peers	median 21.29x across 21 peers — the cross-check, not the input
Arithmetic	base EPS × (1 + guided growth × delivery)¹ × exit multiple

Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.

How to read this

It answers one question. If this management delivers the growth it told its own investors it would, and the market pays what it has historically paid for this company's earnings, where does the arithmetic land? Nothing here is a forecast of the share price.
Three cases, two moving parts. Bear, base and bull vary the delivery — what fraction of guidance managements actually file — and the exit multiple together, because a company that misses its guidance is usually de-rated for missing it. Each case shows the growth rate and the multiple that produced it.
Read the width, not just the middle. A wide gap between bear and bull means the inputs are uncertain, not that the upside is bigger. A narrow range is a more confident statement than a high one.
“Where the market has priced it” puts today's P/E on the company's own historical range. Sitting far below that range is why a scenario can look enormous: the number is then mostly about re-rating, not about delivery, and the board marks those separately.
The bullets underneath are the caveats — a borrowed peer multiple, a thin filed history, an earnings base that carried a one-off. They are the reasons to trust the number less, listed rather than buried.

Not a price target, not a recommendation, and not a forecast of what the stock will do. The field guide covers the method.

What management said

from a third-party research digest · not our own extraction

margin 56%

Gross profit grew by 5% YoY to INR 2,403 million, maintaining a healthy gross margin of 56%.

Call 11-May-2026 · bridge confidence medium · transcript PDF

Coverage

SectorAgricultural Commodities/Milling

Dossiersnone

Guidanceyes

Scenarioyes

Street chatter

unverified · logged from public channels

⭐ Strong Q1 FY27 results driven by segment growth, increased revenue. #NATHBIOGEN - 55 seconds ago

AI-curated filing alert · Not investment advice

Results30 Jul 07:28

⭐ Nath Bio-Genes Q1 2026 profit surges, AGM scheduled. #NATHBIOGEN - 56 seconds ago

AI-curated filing alert · Not investment advice

29 Jul 10:51

NATH BIO-GENES Q1 FY27 : CONS NET PROFIT UP 14.08% AT ₹32.26 CR (YOY), TURNAROUND VS NEAR-BREAKEVEN LOSS OF ₹0.01 CR (QOQ)

Results30 Jul 03:46